Compare REVB & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REVB | VIVS |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.8M |
| IPO Year | 2020 | 2010 |
| Metric | REVB | VIVS |
|---|---|---|
| Price | $0.98 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.1K | ★ 530.8K |
| Earning Date | 05-07-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,603,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.82 |
| 52 Week Low | $0.47 | $0.22 |
| 52 Week High | $2.32 | $3.87 |
| Indicator | REVB | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 35.95 |
| Support Level | $0.96 | N/A |
| Resistance Level | $1.21 | $0.30 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 69.23 | 44.95 |
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.